BioStem reports Q2 prelim revenue of $49.3M
Source: SeekingAlpha
2025-08-14 16:59:47 ET
More on BioStem Technologies
- BioStem Technologies: Huge Growth, Poised To Help Wound Care Field
- Seeking Alpha’s Quant Rating on BioStem Technologies
- Historical earnings data for BioStem Technologies
- Financial information for BioStem Technologies
Read the full article on Seeking Alpha
For further details see:
BioStem reports Q2 prelim revenue of $49.3M
BioStem Technologies Inc
NASDAQ: BSEM
BSEM Trading
2.32% G/L:
$5.2899 Last:
6,999 Volume:
$5.15 Open:
BSEM Latest News
February 20, 2026 07:00:00 am
BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference
February 03, 2026 04:05:00 pm
BioStem Technologies Highlights Alignment with FDA's Openness to Bayesian Statistical Approaches in Clinical Research
January 21, 2026 05:30:00 pm
BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings' Surgical and Wound Care Business
January 07, 2026 04:05:00 pm
BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
BSEM Stock Data
$103,620,347
11,558,982
N/A
N/A
Biotechnology & Life Sciences
Healthcare
US
Pompano Beach
